Specialty pharmaceutical company Sagent Pharmaceuticals has introduced an antineoplastic agent, Docetaxel Injection Concentrate, in three preservative-free vial presentations.
Designed to help reduce medication errors, the product features Sagent's PreventIV Measures packaging and labeling.
Docetaxel Injection Concentrate is indicated as a single agent for locally advanced or metastatic breast cancer after chemotherapy failure with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive breast cancer.
It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer after platinum therapy failure and with cisplatin for unresectable, locally advanced or metastatic untreated non-small cell lung cancer, with prednisone in androgen independent metastatic prostate cancer,
Additionally, it is also indicated with cisplatin and fluorouracil for untreated, advanced gastric adenocarcinoma, including the gastroesophageal junction and with cisplatin and fluorouracil for induction treatment of locally advanced squamous cell carcinoma of the head and neck cancer.
